Consensus analyst ratings for MacroGenics Inc. (NASDAQ: MGNX) lean generally positive, categorized predominantly as a Buy or moderate Outperform. Out of the institutional research firms tracking the biopharmaceutical company, the vast majority recommend initiating or maintaining a buy stance, supported by encouraging developments in its proprietary antibody-drug conjugate pipeline and strategic pharmaceutical partnerships, though a minority maintain neutral hold ratings due to clinical trial execution variables.